- Report
- May 2025
- 193 Pages
Global
From €3174EUR$3,545USD£2,703GBP
€3526EUR$3,939USD£3,004GBP
- Report
- May 2025
- 183 Pages
Global
From €3174EUR$3,545USD£2,703GBP
€3526EUR$3,939USD£3,004GBP
- Report
- May 2025
- 200 Pages
Global
From €2229EUR$2,490USD£1,899GBP
- Report
- April 2025
- 200 Pages
Global
From €4019EUR$4,490USD£3,424GBP
- Report
- April 2025
- 200 Pages
Global
From €4019EUR$4,490USD£3,424GBP
- Report
- June 2025
- 196 Pages
Global
From €5237EUR$5,850USD£4,461GBP
- Report
- June 2025
- 72 Pages
Global
From €5237EUR$5,850USD£4,461GBP
- Report
- August 2024
- 150 Pages
Global
From €2497EUR$2,789USD£2,127GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2686EUR$3,000USD£2,288GBP
- Report
- September 2024
- 117 Pages
Global
From €4028EUR$4,500USD£3,431GBP
- Report
- December 2022
- 66 Pages
Global
From €3133EUR$3,500USD£2,669GBP
- Report
- August 2023
- 336 Pages
Global
From €4163EUR$4,650USD£3,546GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3223EUR$3,600USD£2,745GBP
- Report
- July 2023
- 220 Pages
Global
From €1781EUR$1,990USD£1,517GBP
- Report
- May 2024
- 140 Pages
Global
From €5818EUR$6,499USD£4,956GBP
- Report
- June 2024
- 200 Pages
Global
From €7117EUR$7,950USD£6,062GBP
- Report
- October 2020
- 133 Pages
Global
From €13424EUR$14,995USD£11,434GBP
- Report
- March 2022
- 124 Pages
Global
From €3187EUR$3,560USD£2,715GBP
€3984EUR$4,450USD£3,393GBP
- Report
- February 2022
- 62 Pages
Global
From €3133EUR$3,500USD£2,669GBP
- Report
- January 2024
- 120 Pages
United States
€3133EUR$3,500USD£2,669GBP

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors.
Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more